Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience
| Autor: | André Gilles, Jean-Luc Van Laethem, Pieter Demetter, Carine De Prez, Oriane Blanchard, Isabelle Salmon, Laurine Verset, Marie Le Mercier, Quitterie Fontanges, Bárbara Meléndez, Monique Delos, Nathalie Nagy, Marie-Paule Van Craynest, Marie-Françoise Dehou, Emmanuel Rousseau, Nancy De Nève, Josse Vandenhove, Nicky D'Haene, Calliope Maris |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Neuroblastoma RAS viral oncogene homolog Oncology medicine.medical_specialty Colorectal cancer colorectal cancer medicine.disease_cause DNA sequencing Metastasis 03 medical and health sciences 0302 clinical medicine Targeted ngs Internal medicine medicine Lung cancer business.industry medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Next-generation sequencing next-generation sequencing KRAS business Relevant information Psychiatrie Research Paper |
| Zdroj: | Oncotarget Oncotarget, 9 (29 |
| ISSN: | 1949-2553 |
| Popis: | International guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-EGFR agents for metastatic colorectal cancer (CRC) patients. Daily, new data emerges on the theranostic and prognostic role of molecular biomarkers; this is a strong incentive for a validated, sensitive, and broadly available molecular screening test. Next-generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. We report here our 2 years of clinical practice using NGS results to guide therapeutic decisions. The Ion Torrent AmpliSeq colon/lung cancer panel, which allows mutation detection in 22 cancer-related genes, was prospectively used in clinical practice (BELAC ISO 15189 accredited method). The DNA of 741 formalin-fixed paraffinembedded CRC tissues, including primary tumors and metastasis, was obtained from 14 different Belgian institutions and subjected to targeted NGS. Of the tumors tested, 98% (727) were successfully sequenced and 89% (650) harbored at least one mutation. KRAS, BRAF and NRAS mutations were found in 335 (46%), 78 (11%) and 32 (4%) samples, respectively. These mutation frequencies were consistent with those reported in public databases. Moreover, mutations and amplifications in potentially actionable genes were identified in 464 samples (64%), including mutations in PIK3CA (14%), ERBB2 (0.4%), AKT1 (0.6%), and MAP2K1 (0.1%), as well as amplifications of ERBB2 (0.3%) and EGFR (0.3%). The median turnaround time between reception of the sample in the laboratory and report release was 8 calendar days. Overall, the AmpliSeq colon/lung cancer panel was successfully applied in daily practice and provided reliable clinically relevant information for CRC patients. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|